CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-03-05): Daily cannabis smoking linked with increased steatosis severity

Clinical

Daily cannabis smoking linked with increased steatosis severity

Last Updated: 2008-03-05 12:33:15 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Daily marijuana smoking is associated with increased severity of steatosis in patients with chronic hepatitis C, according to a report in the February issue of Gastroenterology.

"Information about cannabis use should be routinely obtained, and the patients need to be advised of the potential deleterious effects of cannabis on hepatitis C outcome," Dr. Ariane Mallat from Groupe Hospitalier Henri Mondor-Albert Chenevier, Creteil, France told Reuters Health.

Because endocannabinoids have promoted steatosis in experimental models by activating hepatic CB1 receptors, Dr. Mallat and colleagues investigated the relationship between cannabis use and steatosis grade in patients with untreated chronic hepatitis C undergoing liver biopsy.

Nearly a third of the daily cannabis smokers had marked steatosis, compared with 7.7% of occasional cannabis users and 16.0% of nonusers, the authors report.

In logistic regression analysis, daily cannabis use was associated with a doubling of the rate of marked steatosis, whereas occasional use had no significant effect.

The association between daily cannabis use and marked steatosis was independent of viral genotype and persisted after adjustment for alcohol intake.

Not surprisingly, the researchers point out that "cannabinoid use should be discouraged in patients with chronic hepatitis C."

Furthermore, Dr. Mallat said, "This study makes a strong point supporting the potential beneficial effect of CB1 antagonism in the treatment of nonalcoholic fatty liver disease."

In a related editorial, Drs. George Kunos and Bin Gao from the National Institute on Alcohol Abuse and Alcoholism in Bethesda, Maryland write that given these "very interesting findings...clinical trials testing the effectiveness of a CB1 antagonist in combination with antiviral interferon treatment in patients with chronic hepatitis C virus complicated by steatosis and fibrosis may be warranted."

"We are currently investigating the impact of cannabis use on insulin resistance (metabolic and virus-induced) in patients with hepatitis C," Dr. Mallat added.

Gastroenterology 2008;134:432-439,622-625.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.